Company news
TG Therapeutics, Inc. news in 2026
TG Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
November 2, 2026
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
October 23, 2026
TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
October 21, 2026
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
October 12, 2026
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
October 8, 2026
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance
August 3, 2026
TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update
July 29, 2026
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
July 6, 2026
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
June 8, 2026
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
June 3, 2026
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
June 2, 2026
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
June 1, 2026
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
May 27, 2026
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
May 26, 2026
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
May 6, 2026
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
April 30, 2026
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
April 21, 2026
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
April 14, 2026
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
March 18, 2026
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
March 8, 2026
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
March 5, 2026
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
February 25, 2026
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update
February 23, 2026
Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis
February 17, 2026
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
February 8, 2026
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 6, 2026
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
January 27, 2026
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
January 13, 2026
TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
Calls in 2026
Decks in 2026
- 10th Joint ACTRIMS-ECTRIMS Meeting 2026
Conference · 15 slides · Oct 23, 2026